Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8208263 | 0.85 | ALDH1A1 (0.39) | MEN1KMT2ATSHRALDH1A1TDP1 | |
| SCHEMBL13437589 | 0.84 | TSHR (0.39) | MEN1KMT2ATSHRALDH1A1TDP1 | |
| SCHEMBL6986482 | 0.84 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL3302109 | 0.78 | TSHR (0.42) | MEN1KMT2ATSHRALDH1A1TDP1 | |
| SCHEMBL2151901 | 0.75 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL2757913 | 0.74 | MEN1 (0.34) | MEN1KMT2ATSHRALDH1A1TDP1 | |
| Cyanate SCHEMBL28170473 | 0.74 | CA1 (0.35) | TSHRALDH1A1 | |
| SCHEMBL10114805 | 0.73 | MEN1 (0.33) | MEN1KMT2ATSHR | |
| SCHEMBL19881255 | 0.73 | MEN1 (0.37) | MEN1KMT2ATSHR | |
| SCHEMBL21561633 | 0.73 | THRB (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6495576-B2 | N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | disclosed |
| US-20020165264-A1 | Aminal diones as potassium channel openers | ABBOTT LABORATORIES | 2002-11-07 | — | — | US | disclosed |
| US-20020147230-A1 | Aminal Diones as potassium channel openers | ABBOTT LABORATORIES | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147230-A1 | Aminal Diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | MEN1 773/4885KMT2A 1875/4885TSHR 3942/4885 |
| US-20020165264-A1 | Aminal diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | MEN1 773/4885KMT2A 1875/4885TSHR 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.